Table 1.

Clinical and immunohistologic features

Whole cohort (N = 74)Patients with colonoscopic follow-up (N = 39)
VariablesPercentage (95% CI)Percentage (95% CI)P
Age, y0.09
 Median6564
 Range32–8933–89
Sex0.68
 Male57 (45–68)59% (42–74)
 Female43 (32–55)41% (26–58)
Number of polyps0.89
 159 (47–71)62 (45–77)
 2–441 (29–53)38 (23–55)
Size of polyps (largest diameter, mm)0.49
 Median33
 Range1–61–5
Localization0.60
 Proximal colon20 (12–31)18 (8–34)
 Distal colon80 (69–88)82 (66–82)
Occurrence of metachronous adenomaNA41 (26–59)
Loss of expression of MLH10 (0–5)a0 (0–9)aNC
Expression of progastrin0.26
 No/low expression (<10%)26 (16–37)18 (8–34)
 Moderate expression (10%–50%)34 (23-46)36 (21-53)
 High expression (>50%)40 (29–53)46 (30–63)

NOTE: Progastrin expression was recorded as “No/low moderate or high expression” with the percentage of positive colonic epithelial cells. The “physiological” threshold of progastrin expression was determined using the 95th percentile of percentage of stained cells in normal colonic tissue (10% of positive cells). The χ2 tests (for categorical variables) and Student t tests (for continuous variables) were conducted to compare clinical and immunohistologic features between patients who had a colonoscopic follow-up and those who had not. 95% CI: Binomial exact 95% CI was calculated for each percentage.

Abbreviations: NA, not available; NC, not calculable.

  • aOne-sided, 97.5% CI.